Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors

Oster, James R.; Materson, Barry J.

doi:10.1001/archinte.1992.00400160022006

Cited by 49 publications

(7 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although arrhythmia 35,36 , hyponatremia 37,38 , the size of ventricular cavities 39,40 , and serum catecholamin levels 41 do play key roles in the long term course of cardiopathy patients, those variables may also influence decompensation in the acute phase. In our population we have observed that hyponatremia, and serum sodium lower than 129 mEq/l double mortality rate as compared to patients reporting normal sodium levels (Table 5).…”

Section: Terzi Et Al Severe Heart Failure At Intensive Therapy Unit -mentioning

confidence: 99%

Insuficiência cardíaca grave em unidade de terapia intensiva: existe um índice prognóstico ideal?

Terzi

Lage

Dragosavac

et al. 2006

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

Section: Terzi Et Al Severe Heart Failure At Intensive Therapy Unit -mentioning

confidence: 99%

Insuficiência cardíaca grave em unidade de terapia intensiva: existe um índice prognóstico ideal?

Terzi

Lage

Dragosavac

et al. 2006

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

“…Renal function can deteriorate acutely when ACE inhibitor therapy is initiated [22][23][24][25] or in patients receiving chronic ACE inhibitor therapy, particularly in patients with CHF. ARF can occur even if ACE inhibitor therapy has been uneventful for months or years.…”

Section: Arf Due To Ace Inhibitor Therapymentioning

confidence: 99%

Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy

Schoolwerth¹,

Sica²,

Ballermann³

et al. 2001

Circulation

312

View full text Add to dashboard Cite

“…A second and more typical pattern of hyponatremia correction in CHF is characterized by a net loss of water in association with ACE inhibitor-related increases in renal blood flow and the glomerular filtration rate. 26,29 The specific effect of ACE inhibitors and/or AT 1 -RAs on the thirst drive has been poorly studied in CHF. Without head-to-head studies of the various compounds that constitute these classes, there is no realistic way to establish a treatment hierarchy for these medications in the hyponatremic CHF patient.…”

Section: Hyponatremia In Chf Patients Is Mainly Due To a Limited Abilmentioning

confidence: 99%

Angiotensin II and Thirst: Therapeutic Considerations

Sica

2001

Congestive Heart Failure

View full text Add to dashboard Cite

Angiotensin II is the effector peptide of the renin-angiotensin system and is involved in a wide range of physiologic functions that relate to volume control. In this regard, angiotensin II maintains and regulates salt and water balance, is critically involved in cardiovascular function, and governs thirst. When present in excess, angiotensin II can pathologically influence each of these functions. The role of angiotensin II in controlling sodium balance, in both renal insufficiency states and congestive heart failure, is clearly recognized. Alternatively, it is poorly appreciated that angiotensin II plays an important role in both normal and pathologic thirst states. The latter is a potential problem in both end-stage renal disease and congestive heart failure. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor antagonists (AT1-RAs) have both been shown to reduce abnormal thirst drive. Whether an ACE inhibitor or an AT1-RA lessens thirst drive to any significant degree relates to its capacity to penetrate the blood-brain barrier. Head-to-head comparisons of ACE inhibitors and AT1-RAs, as to their effect on thirst drive, have not been undertaken in a systematic fashion; thus, until otherwise established, the effect of these compounds on thirst should be viewed as a class effect, albeit one that is likely to be dose-dependent. (c)2001 CHF, Inc.

show abstract

Renal and Electrolyte Complications of Congestive Heart Failure and Effects of Therapy With Angiotensin-Converting Enzyme Inhibitors

Cited by 49 publications

References 81 publications

Insuficiência cardíaca grave em unidade de terapia intensiva: existe um índice prognóstico ideal?

Insuficiência cardíaca grave em unidade de terapia intensiva: existe um índice prognóstico ideal?

Renal Considerations in Angiotensin Converting Enzyme Inhibitor Therapy

Angiotensin II and Thirst: Therapeutic Considerations

Contact Info

Product

Resources

About